Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY |
| 16 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT05015426 | Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT | active not recruiting | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05025488 | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 7 | Marina KremyanskayaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05048368 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function | withdrawn | Phase 1 | 0 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05050097 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MonumenTAL-2) | active not recruiting | Phase 1 | 166 | Janssen Research & Development, LLCINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT05303467 | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM(FRONTIER) | recruiting | Phase 1 | 36 | Boston Scientific CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05421663 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 166 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05424822 | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 1 | 167 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05432804 | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | recruiting | Phase 1 / Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05507827 | Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL | active not recruiting | Phase 1 | 22 | Melody SmithOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | recruiting | Phase 1 / Phase 2 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | completed | Phase 1 | 79 | Incendia TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05867251 | Study of AVZO-021 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 430 | Avenzo Therapeutics, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT05872295 | IKS014 in Advanced Solid Tumors That Express HER2 | recruiting | Phase 1 | 165 | Iksuda Therapeutics Ltd.INDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT05981703 | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 337 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT06110793 | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 433 | BeOne MedicinesINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06148038 | CBD for Breast Cancer Primary Tumors | recruiting | Phase 1 | 84 | Medical University of South CarolinaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06149481 | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06384807 | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 500 | Biohaven Therapeutics Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06425991 | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-10) | active not recruiting | Phase 1 | 108 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06484062 | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06651229 | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | active not recruiting | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | recruiting | Phase 1 / Phase 2 | 258 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT06726161 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC(GPC3) | recruiting | Phase 1 / Phase 2 | 590 | RayzeBio, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07145112 | Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma | recruiting | Phase 1 | 25 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07181681 | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 63 | BeOne MedicinesINDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT07222267 | An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 86 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07226349 | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 105 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | recruiting | Phase 1 | 260 | IDEAYA BiosciencesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07293754 | An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors(RaPTR-101) | recruiting | Phase 1 / Phase 2 | 150 | Repertoire Immune MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07346157 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) | recruiting | Phase 1 / Phase 2 | 69 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07414836 | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 84 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 132 | PfizerINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07439653 | A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | TORL Biotherapeutics, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | recruiting | Phase 1 | 250 | PfizerINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 265 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07601334 | Safety and Activity of HF50 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 45 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | recruiting | Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07843550 | A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy | not yet recruiting | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07844447 | A Study of RT036 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 308 | Shanghai Ruotuo Biosciences Co., Ltd.INDUSTRY | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07845266 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 13 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02123758 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 57 | Aragon Pharmaceuticals, Inc.INDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials